Veradermics MANE Income Statement
| TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|
| —— | —— | —— | $28.91M+24.2% | ||
| —— | —— | —— | $4.09M+17.0% | ||
| —— | —— | —— | $33M+23.2% | ||
| —— | —— | —— | -$33M-23.2% | ||
| $0-100% | $146.25K-50.0% | $292.5K-33.3% | $438.75K-25.0% | ||
| —— | —— | —— | $732.5K+153% | ||
| —— | —— | —— | -$32.27M-21.8% | ||
| —— | —— | —— | $0— | ||
| —— | —— | —— | -$32.27M-21.8% | ||
| —— | —— | —— | -$47.58-28.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Veradermics profitable?
- Veradermics is not currently profitable: it reported a net loss of $52.9M over the trailing twelve months.
- What is Veradermics 's earnings per share?
- Veradermics 's diluted EPS over the trailing twelve months is $-39.63.
- Where does Veradermics 's income statement data come from?
- Every line is extracted from Veradermics 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.